Recurrent Melanoma Completed Phase Trials for Sargramostim (DB00020)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)CompletedNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00006243Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant MelanomaTreatment